← Back to Clinical Trials
Recruiting NCT07605715

NCT07605715 Transcatheter vs. Surgical Treatment of Degenerative Mitral Regurgitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07605715
Status Recruiting
Phase
Sponsor Cedars-Sinai Medical Center
Condition Degenerative Mitral Valve Disease
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2025-02-19
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2025-02-19 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to compare the outcomes of transcatheter edge-to-edge repair (TEER) versus surgical mitral valve repair for degenerative mitral regurgitation (DMR) over the long term. The study aims to: 1. Evaluate the effectiveness and safety of TEER versus surgery in patients with DMR over long term. 2. Investigate the predictors of left ventricular dysfunction and clinical outcomes using advanced imaging techniques, such as cardiac MRI 3. Assess patient-reported recovery and quality of life outcomes using validated tools. The study focuses on improving care strategies for patients with DMR, particularly those at higher surgical risk, by identifying optimal treatment approaches and predictors of recovery.

Eligibility Criteria

Inclusion Criteria: * Patients older than 60 years who have DMR will be included in the study Exclusion Criteria: * Patients with prior history of mitral intervention or surgery will be excluded. * Patient records flagged "break the glass" or "research opt out" will be excluded. * Persons with allergy to animal dander or animal-instigated asthma will be excluded.

Contact & Investigator

Central Contact

Aakriti Gupta, M.D.

✉ aakriti.gupta@cshs.org

📞 267-442-8776

Frequently Asked Questions

Who can join the NCT07605715 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Degenerative Mitral Valve Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07605715 currently recruiting?

Yes, NCT07605715 is actively recruiting participants. Contact the research team at aakriti.gupta@cshs.org for enrollment information.

Where is the NCT07605715 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT07605715 clinical trial?

NCT07605715 is sponsored by Cedars-Sinai Medical Center. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology